Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Somatogen (SMTG) -- Ignore unavailable to you. Want to Upgrade?

To: Timothy Kross who wrote (335)	12/4/1997 9:26:00 AM
From: Jonathan Rothschild	Read Replies (1) \| Respond to of 442

I anyone aware of the huge private financing of Biopure, a private company working on blood substitutes in late phase 3 for veterinary use and early phase 3 for human. This was the biggest financing in the history of the biotechnology industry. Somatogen popped at the end of the day. I think the competition is good. We need more validation for the entire blood substitute market. I expect Baxter to make a move soon and do a deal with Somatogen. They are an ideal candidate for a partner. The advantages for them are a second generation product with unlimited capacity, their sales and distribution clout with hospitals, their engineering expertise, their cash position and their history of doing deals with biotech. They also received some negative press regarding their ongoing lawsuit with Cellpro and need to do a contirbutory deal within the biotech sector. Biopure will probably go public soon and the v.cs will get out.